RNAi to treat SARS‐CoV‐2—variant proofing the next generation of therapies

There is an urgent need to bring new antivirals to SARS‐CoV‐2 to the market. Indeed, in the last 3 months, we have seen at least two new antivirals approved, molnupiravir and paxlovid. Both are older established antivirals that show some efficacy against SARS‐CoV‐2. The work by Chang et al (2022) in...

Descripción completa

Detalles Bibliográficos
Autores principales: McMillan, Nigel A J, Morris, Kevin V, Idris, Adi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
News & Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988212/
https://www.ncbi.nlm.nih.gov/pubmed/35285158
http://dx.doi.org/10.15252/emmm.202215811

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988212/
https://www.ncbi.nlm.nih.gov/pubmed/35285158
http://dx.doi.org/10.15252/emmm.202215811

Ejemplares similares